An Expert Report on Olive Oil (DB09567) as a Biopharmaceutical Agent and Therapeutic Modality

Executive Summary

Olive Oil (DB09567), a substance long recognized for its culinary and traditional medicinal value, has emerged as a significant agent within the modern pharmaceutical and biotechnology landscape. This report provides a comprehensive scientific and clinical analysis of olive oil, elucidating its multifaceted role that extends far beyond basic nutrition. Classified by DrugBank as a "Biotech" product, its identity in contemporary medicine is defined by two primary functions: first, as an Active Pharmaceutical Ingredient (API) in parenteral nutrition emulsions, providing essential calories and fatty acids to vulnerable patient populations; and second, as a critical, high-purity excipient and raw material that enables the formulation and manufacture of advanced therapeutics, including sensitive biologic drugs and sustainable vaccine adjuvants.

The pharmacological profile of olive oil is uniquely dualistic. Its major lipid components, predominantly glycerides of oleic acid, provide metabolic energy. However, its therapeutic potency is largely derived from a complex mixture of minor bioactive constituents, including the potent anti-inflammatory phenol oleocanthal, which exhibits a mechanism of action similar to ibuprofen, and a broad array of other polyphenols like hydroxytyrosol and oleuropein that confer significant antioxidant and immunomodulatory effects. This synergistic interplay of components underpins the extensive clinical evidence supporting its use.